Amedisys - AMED Stock Forecast, Price & News

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last year. There are currently 2 sell ratings, 3 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AMED shares.
View AMED analyst ratings or view top-rated stocks.

15 brokers have issued twelve-month price objectives for Amedisys' stock. Their AMED share price forecasts range from $95.00 to $213.00. On average, they predict the company's stock price to reach $156.25 in the next twelve months. This suggests a possible upside of 61.4% from the stock's current price.
View analysts price targets for AMED or view top-rated stocks among Wall Street analysts.

Amedisys' stock was trading at $161.88 at the beginning of 2022. Since then, AMED stock has decreased by 40.2% and is now trading at $96.79.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our AMED earnings forecast.

Amedisys, Inc. (NASDAQ:AMED) released its earnings results on Wednesday, July, 27th. The health services provider reported $1.47 earnings per share for the quarter, beating analysts' consensus estimates of $1.23 by $0.24. The health services provider had revenue of $557.89 million for the quarter, compared to analysts' expectations of $583.12 million. Amedisys had a trailing twelve-month return on equity of 17.81% and a net margin of 6.33%. Amedisys's quarterly revenue was down 1.1% compared to the same quarter last year. During the same quarter last year, the company earned $1.69 earnings per share.

Amedisys announced that its board has initiated a stock repurchase plan on Wednesday, August 4th 2021, which authorizes the company to repurchase $100,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to buy up to 1.2% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company's leadership believes its shares are undervalued.

Amedisys updated its FY 2022 earnings guidance on Thursday, August, 4th. The company provided earnings per share (EPS) guidance of $5.23-$5.45 for the period, compared to the consensus estimate of $5.30. The company issued revenue guidance of $2.29 billion-$2.31 billion, compared to the consensus revenue estimate of $2.35 billion.

478 employees have rated Amedisys Chief Executive Officer Paul B. Kusserow on Glassdoor.com. Paul B. Kusserow has an approval rating of 79% among the company's employees. 60.0% of employees surveyed would recommend working at Amedisys to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Adobe (ADBE), Intel (INTC), QUALCOMM (QCOM), Broadcom (AVGO), Cisco Systems (CSCO) and Home Depot (HD).

Amedisys trades on the NASDAQ under the ticker symbol "AMED."

Shares of AMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AMED stock can currently be purchased for approximately $96.79.

Amedisys (NASDAQ:AMED) has a market capitalization of $3.14 billion and generates $2.21 billion in revenue each year. The health services provider earns $209.07 million in net income (profit) each year or $4.29 on an earnings per share basis.

The company employs 21,000 workers across the globe.

Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The official website for the company is www.amedisys.com. The health services provider can be reached via phone at (225) 292-2031, via email at ir@amedisys.com, or via fax at 225-292-8163.